Tag: Gervasio Lamas

Son of (the unethical and unscientific) Trial To Assess Chelation Therapy rears its ugly head to the tune of $37 million

First, the NCCIH and NHLBI spend $30 million on a clinical trial of quackery for cardiovascular disease that produces predictably negative to at best equivocal results. Then that result, apparently, is enough to justify wasting another $37 million on a followup study—while dozens of other deserving studies go unfunded. Meanwhile STAT News lionizes the principal investigator of both trials as a brave...

/ December 28, 2016

The Hippocrates Health Institute: Cancer quackery finally under the spotlight, but will it matter?

I first came across Brian Clement, the proprietor of the Hippocrates Health Institute in West Palm Beach, Florida, a little more than a year ago based on the story of Stephanie O’Halloran. Ms. O’Halloran was—word choice unfortunately intentional—a 23-year-old mother of an 18 month old child from Ireland who was diagnosed with stage IV breast cancer in 2013, with metastases to her...

/ February 23, 2015

Of the Trial to Assess Chelation Therapy, Bayes, the NIH, and Human Studies Ethics

An experiment is ethical or not at its inception; it does not become ethical post hoc—ends do not justify means. ~ Henry K. Beecher A couple of weeks ago, Dr. Josephine Briggs, the Director of the National Center for Complementary and Alternative Medicine (NCCAM), posted a short essay on the NCCAM Research Blog touting the results of the Trial to Assess Chelation...

/ May 30, 2014

The result of the Trial to Assess Chelation Therapy (TACT): As underwhelming as expected

Chelation therapy. It’s one of the most common quackeries out there, used by a wide variety of practitioners for a wide variety of ailments blamed on “heavy metal toxicity.” Chelation therapy, which involves using chemicals that can bind to the metal ions and allow them to be excreted by the kidneys, is actually standard therapy for certain types of acute heavy metal...

/ November 5, 2012

Of SBM and EBM Redux. Part II: Is it a Good Idea to test Highly Implausible Health Claims?

Review This is the second post in a series* prompted by an essay by statistician Stephen Simon, who argued that Evidence-Based Medicine (EBM) is not lacking in the ways that we at Science-Based Medicine have argued. David Gorski responded here, and Prof. Simon responded to Dr. Gorski here. Between that response and the comments following Dr. Gorski’s post it became clear to...

/ December 10, 2010